Literature DB >> 12471103

The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.

Olaf Stüve1, Sawsan Youssef, Anthony J Slavin, Chelsea L King, Juan Carlos Patarroyo, David L Hirschberg, W June Brickey, Jeanne M Soos, Janet F Piskurich, Harold A Chapman, Scott S Zamvil.   

Abstract

The role of the MHC class II transactivator (CIITA) in Ag presentation by astrocytes and susceptibility to experimental autoimmune encephalomyelitis (EAE) was examined using CIITA-deficient mice and newly created transgenic mice that used the glial fibrillary acidic protein promoter to target CIITA expression in astrocytes. CIITA was required for class II expression on astrocytes. Like class II-deficient mice, CIITA-deficient mice were resistant to EAE by immunization with CNS autoantigen, although T cells from immunized CIITA-deficient, but not class II-deficient, mice proliferated and secreted Th1 cytokines. CIITA-deficient splenic APC presented encephalitogenic peptide to purified wild-type encephalitogenic CD4(+) T cells, indicating that CIITA-independent mechanisms can be used for class II-restricted Ag presentation in lymphoid tissue. CIITA-deficient mice were also resistant to EAE by adoptive transfer of encephalitogenic class II-restricted CD4(+) Th1 cells, indicating that CIITA-dependent class II expression was required for CNS Ag presentation. Despite constitutive CIITA-driven class II expression on astrocytes in vivo, glial fibrillary acidic protein-CIITA transgenic mice were no more susceptible to EAE than controls. CIITA-transfected astrocytes presented peptide Ag, but in contrast to IFN-gamma-activated astrocytes, they could not process and present native Ag. CIITA-transfected astrocytes did not express cathepsin S without IFN-gamma activation, indicating that CIITA does not regulate other elements that may be required for Ag processing by astrocytes. Although our results demonstrate that CIITA-directed class II expression is required for EAE induction, CIITA-directed class II expression by astrocytes does not appear to increase EAE susceptibility. These results do not support the role of astrocytes as APC for class II-restricted Ag presentation during the induction phase of EAE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12471103     DOI: 10.4049/jimmunol.169.12.6720

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation.

Authors:  Angelo A Chora; Paulo Fontoura; Andreia Cunha; Teresa F Pais; Sílvia Cardoso; Peggy P Ho; Lowen Y Lee; Raymond A Sobel; Lawrence Steinman; Miguel P Soares
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

Review 2.  MDSC in autoimmunity.

Authors:  James G Cripps; James D Gorham
Journal:  Int Immunopharmacol       Date:  2011-02-21       Impact factor: 4.932

Review 3.  Antigen-presenting cell diversity for T cell reactivation in central nervous system autoimmunity.

Authors:  Ari Waisman; Lisa Johann
Journal:  J Mol Med (Berl)       Date:  2018-11-01       Impact factor: 4.599

4.  Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Authors:  Klaus Lehmann-Horn; Helena C Kronsbein; Martin S Weber
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

5.  Role of the MHC2TA gene in autoimmune diseases.

Authors:  Alfonso Martínez; Marta Sánchez-Lopez; Jezabel Varadé; Ana Mas; M Carmen Martín; Virginia de Las Heras; Rafael Arroyo; Juan Luis Mendoza; Manuel Díaz-Rubio; Benjamín Fernández-Gutiérrez; Emilio G de la Concha; Elena Urcelay
Journal:  Ann Rheum Dis       Date:  2006-09-29       Impact factor: 19.103

Review 6.  Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis.

Authors:  Rose Gilbert; Ahmed Al-Janabi; Oren Tomkins-Netzer; Sue Lightman
Journal:  Porto Biomed J       Date:  2017-03-01

7.  Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling.

Authors:  Wei Hu; Stefan Nessler; Bernhard Hemmer; Todd N Eagar; Lawrence P Kane; S Rutger Leliveld; Andreas Müller-Schiffmann; Anne R Gocke; Amy Lovett-Racke; Li-Hong Ben; Rehana Z Hussain; Andreas Breil; Jeffrey L Elliott; Krishna Puttaparthi; Petra D Cravens; Mahendra P Singh; Benjamin Petsch; Lothar Stitz; Michael K Racke; Carsten Korth; Olaf Stüve
Journal:  Brain       Date:  2010-02-09       Impact factor: 13.501

8.  Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica.

Authors:  Patricia A Nelson; Mojgan Khodadoust; Thomas Prodhomme; Collin Spencer; Juan Carlos Patarroyo; Michel Varrin-Doyer; Joseph D Ho; Robert M Stroud; Scott S Zamvil
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

Review 9.  Astrocytes: Integrative Regulators of Neuroinflammation in Stroke and Other Neurological Diseases.

Authors:  Egle Cekanaviciute; Marion S Buckwalter
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

10.  IFN-γ ameliorates autoimmune encephalomyelitis by limiting myelin lipid peroxidation.

Authors:  Rebecca A Sosa; Cathi Murphey; Rachel R Robinson; Thomas G Forsthuber
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.